mitacs elevate provides two years of postdoc funding valued at $60,000/year plus extensive customized professional development training ($7,500/year non-cash value).

postdocs:

• manage a long-term collaborative research project with a company or not-for-profit
• develop business-ready skills in leadership, financial literacy, management and negotiation, project management, problem solving and much more

 
key deadlines:

• june 19, 2019 - intent to apply and conflict of interest declaration deadline
• july 17, 2019 - full applications due

 
for questions or more information, please contact us at elevate@mitacs.ca.  

sshrc and the canadian environmental assessment agency (ceaa) have launched this knowledge synthesis grants (ksg) competition to stimulate social sciences and humanities research that will help inform best practices related to environmental and impact assessments. environmental assessment and impact assessment (which take into consideration a broader range of factors, such as socio-economic) are planning and decision-making tools to minimize or avoid the potential adverse environmental effects of a project and to maximize positive impacts and incorporate environmental and other factors into decision-making.

the fy19 defense appropriation provides $7.5 million (m) to the department of defense epilepsy research program (erp) to understand the causative links between traumatic brain injury (tbi) and epilepsy so that post-traumatic epilepsy (pte) will be both preventable and treatable.  as directed by the office of the assistant secretary of defense for health affairs, the defense health agency, j9 research and development directorate manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation.  the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp) at the u.s. army medical research and materiel command (usamrmc).

fy19 erp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov website.

applications should also address at least one of the erp fy19 focus areas.  an application that proposes research outside of the fy19 focus areas is acceptable, as long as the applicant provides a strong rationale.  the focus areas will be mechanism-specific.

the erp fy19 focus areas are as follows:

basic research: tools intended to better inform or improve upon how post-traumatic epilepsy research can be performed:

• hardware and/or software platforms that will improve seizure detection, characterization, or diagnosis
• bioinformatics strategies, to include machine learning, that will improve access, annotation, curation and visualization of large and novel datasets from single or multiple sources
• development of new models or better characterization of existing etiologically relevant models for pte
• improved characterization of the circuits involved in pte

markers and mechanisms:  identifying markers or mechanisms via preclinical models that address pte, which may include the following:

• biomarkers
• therapeutic targets for epilepsy prevention
• early detection
• diagnosis
• prognosis
• comorbidity
• mortality
• risk stratification

epidemiology:  epidemiological characterization of pte following tbi, which may include the following:

• risk factors such as demographics, genetics, anatomy, pathology, or type of injury
• differentiation of pte and psychogenic non-epileptic seizures (pnes)
• outcomes including latency to epilepsy, comorbidities, and mortality
• pre-existing conditions including psychological and psychiatric risk factors
• treatment and healthcare outcomes research

longitudinal studies:  studies of the natural evolution of pte, which may include the following:

• seizure frequency and severity
• demographics, genetics, anatomy, pathology, or type of injury
• comorbidities (e.g., depression, functional deficits, sleep disorders, major illness)
• latency between type of injury and pte
• mortality
• treatment and healthcare outcomes research
• quality of life of individuals with pte and their caregivers

https://cdmrp.army.mil/funding/erp

idea development award – letter of intent due june 26, 2019

level i:  the principal investigator must be at or above the level of postdoctoral fellow (or equivalent), but below the level of assistant professor (or equivalent).  

level ii:  the principal investigator must be an independent investigator at or above the level of assistant professor (or equivalent).

intent:  the intent of the fy19 erp ida is to solicit novel, innovative research to understand the magnitude and underlying mechanisms of pte. the work should innovatively challenge existing research paradigms or exhibit high levels of creativity within the contexts of the erp’s mission and vision.

• ·       level i is intended to support high-risk or high-gain research from early-career researchers.
• ·       level ii is intended to support a more mature, hypothesis-driven research project.

the following focus areas are open to both levels:

• ·       basic research
• ·       epidemiology
• ·       markers and mechanisms
• ·       longitudinal studies
• ·       preliminary data, while not required, are encouraged for both levels.
• ·       note: research focusing on interventional clinical trials (e.g., pharmacological interventions) is strongly discouraged.

level i:

• ·       maximum funding of $300,000 for direct costs (plus indirect costs).
• ·       maximum period of performance is 3 years.
• ·       indirect costs may be proposed in accordance with the institution's rate agreement.

level ii:

• ·       maximum funding of $500,000 for direct costs (plus indirect costs).
• ·       maximum period of performance is 3 years.
• ·       indirect costs may be proposed in accordance with the institution's rate agreement.

research partnership award – letter of intent due june 26, 2019

the principal investigator must be an independent investigator at or above the level of assistant professor (or equivalent).

intent:  to create an avenue for collaborative research partnerships between/among investigators to address a research problem or question in a manner that would be unachievable through separate efforts. 

• ·       level i is intended to support preclinical or pre-validation research
• ·       level ii is intended to support research requiring access to a patient cohort for a prospective study.

applications must include clearly stated plans for interactions between the partners. the plans must include communication, coordination of research progress and results, and data sharing between all investigators and organizations participating in the project.

the following focus areas are open to both levels i and ii:

• ·       epidemiology
• ·       markers and mechanisms
• ·      longitudinal studies
• ·      preliminary data are required
• ·      note: research focusing on interventional clinical trials (e.g., pharmacologic interventions)  is strongly discouraged.

level i:

• ·       maximum funding of $1.3m for total costs.
• ·       maximum period of performance is 3 years.
• ·       indirect costs may be proposed in accordance with the institution's rate agreement.

level ii:

• ·       maximum funding of $2.0m in total costs.
• ·       maximum period of performance is 4 years.
• ·       indirect costs may be proposed in accordance with the institution's rate agreement.

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final program announcements and general application instructions available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrmc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the erp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp help desk 
301-682-5507 
help@ebrap.org

the fiscal year 2019 (fy19) defense appropriation provides $30 million (m) to the department of defense peer reviewed orthopaedic research program (prorp) to support the most significant gaps in care for the leading burden of injury and for facilitating return to duty by funding innovative, high-impact, clinically relevant research to advance optimal treatment and rehabilitation from musculoskeletal injuries sustained during combat and combat-related activities.  the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp) at the u.s. army medical research and materiel command (usamrmc). 

fy19 prorp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov.

the prorp will solicit research applications that specifically address at least one of the following fy19 focus areas:

1. 1.    compartment syndrome models: diagnostic and/or treatment strategies developed in a large animal model that replicates compartment syndrome.  model system should be clinically relevant and scientifically reproducible.

1. 2.    limb stabilization and protection: development of rapid limb stabilization and novel wound protectants for severely wounded limbs to enable transport at the point of need.

1. 3.    retention on duty strategies: development and/or optimization of battlefield-feasible diagnostic capabilities, decision support tools, interventions, and/or rehabilitation strategies that can facilitate retention on duty for common combat-related musculoskeletal injuries.  (biomarker studies are excluded.)

1. 4.    skin-implant interface: identification of best practices to address infection at the skin-implant interface for osseointegrated prosthetic limbs.

1. 5.    translation of early findings: translation of early research findings in orthopaedic surgical care topic areas (volumetric muscle loss, compartment syndrome, and soft tissue trauma) to move the research toward clinical trials and clinical practice.

1. 6.    tissue regeneration therapeutics: development of advanced tissue regeneration therapeutics in nerve, muscle, and/or composite tissue for the restoration of traumatically injured extremities (excludes isolated bone tissue engineering studies).

the following fy19 prorp award mechanisms are planned for release (note that focus area requirements vary by award mechanism):

https://cdmrp.army.mil/funding/prorp

applied research award- preproposal is due june 26, 2019

independent investigators at all academic levels (or equivalent)

clinical trial award – preproposal due june 26, 2029

independent investigators at all academic levels (or equivalent)

pre-application is required; full application submission is by invitation only.

clinical translational research award – preproposal due june 26, 2019

independent investigators at all academic levels (or equivalent)

pre-application is required; full application submission is by invitation only.

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline. all applications must conform to the final program announcements and general application instructions available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrmc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the prorp or other cdmrp-administered programs, please visit the cdmrp website(https://cdmrp.army.mil).

point of contact:

cdmrp help desk

301-682-5507 
help@ebrap.org

the fy19 defense appropriation provides $10 million (m) to the department of defense (dod) melanoma research program (mrp) to support innovative, high-impact melanoma research. as directed by the office of the assistant secretary of defense for health affairs, the defense health agency j9, research and development directorate manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation. the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp) at the u.s. army medical research and materiel command (usamrmc).

fy19 mrp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov website.

the fy19 mrp focus areas are listed below:

• precursor lesions, melanomagenesis, host factors, and the tumor microenvironment (e.g., melanoma instigators, ultraviolet [uv] exposure, other instigators)
• melanoma primary tumor evolution (e.g., dormancy, heterogeneity, metabolism, epigenetic dysregulation, cell death)
• therapeutic prevention
• minimal residual disease
• rare melanomas (e.g., uveal, acral, leptomeningeal disease, pediatric, adolescent and young adult [aya], mucosal)

the mrp challenges the research community to redefine the concept of prevention and has issued a fy19 mrp challenge statement that should be considered when responding to the fy19 mrp focus areas and funding opportunities.

https://cdmrp.army.mil/funding/mrp

idea award – preproposal due july 26, 2019

independent investigators with a faculty-level appointment (or equivalent)

• ·        preproposal is required; application submission is by invitation only.
• ·        supports new ideas that represent innovative, high-risk/high-gain approaches to melanoma research.
• ·        emphasis on innovation and impact
• ·        preliminary data are not required.
• ·        clinical trials are not allowed.
• ·       the maximum allowable funding for the entire period of performance is $300,000 for direct costs
• ·       indirect costs may be proposed in accordance with the institution’s negotiated rate agreement
• ·       maximum period of performance is 3 years

team science award – preproposal due july 26, 2019

at least two and up to three investigators must partner in one overarching multidisciplinary research study.

initiating principal investigator (pi):

independent investigators at or above the level of associate professor (or equivalent).

partnering pi: independent investigators at or above the level of assistant professor (or equivalent).

post-doctoral fellows are not eligible to be partnering pis.

• ·      preproposal is required; application submission is by invitation only.
• ·      supports new or existing partnerships between two or three independent investigators focusing research across the whole research spectrum.
• ·      investigators are expected to demonstrate within the application, the synergistic components (i.e., leveraging disciplines, expertise or critical resources) that will significantly advance the project such that the research outcomes as a whole will be realized rapidly and efficiently and could not otherwise be accomplished through independent efforts of a single investigator.
• ·      emphasis on synergy, multi-disciplinary research, and impact
• ·      inclusion of an independent early career investigator is encouraged.
• ·      inclusion of at least one military or u.s. department of veterans affairs (va) investigator is encouraged.
• ·      preliminary data are required.
• ·      clinical trials are not allowed.
• ·       the maximum allowable funding for the entire period of performance is $700,000 for direct costs
• ·       indirect costs may be proposed in accordance with the institution’s negotiated rate agreement
• ·       maximum period of performance is 3 years

translational research award – preproposal is due july 26, 2019

independent investigators at or above the level of assistant professor (or equivalent)

• ·      preproposal is required; application submission is by invitation only.
• ·      supports studies aiming to leverage existing biobanks, biorepositories, ongoing or completed clinical trials to address a translational question or problem in melanoma.
• ·      emphasis on translation and impact.
• ·      inclusion of dod or va participation is encouraged.
• ·      preliminary data is required.
• ·      clinical trials are not allowed.
• ·      the maximum allowable funding for the entire period of performance is $600,000 for direct costs
• ·      indirect costs may be proposed in accordance with the institution’s negotiated rate agreement
• ·      maximum period of performance is 3 years

a pre-application (letter of intent or pre-proposal) is required and must be submitted through the electronic biomedical research application portal (ebrap) athttps://ebrap.org prior to the pre-application deadline. all applications must conform to the final program announcements and general application instructions available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrmc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage athttps://ebrap.org.  for more information about the mrp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp help desk 
301-682-5507 
help@ebrap.org

the fy19 defense appropriation provides $22 million (m) to the department of defense gulf war illness research program (gwirp) to support research addressing gulf war illness pathobiology, diagnosis, and treatment.  as directed by the office of the assistant secretary of defense for health affairs, the defense health agency j9, research and development directorate manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation. the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp) at the u.s. army medical research and materiel command (usamrmc).

fy19 gwirp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov website.

https://cdmrp.army.mil/funding/gwirp

idea award – preapplication is due july 12, 2019

independent investigators at all academic levels

• ·        supports innovative high-risk/high-reward research in the earliest stages of development that will contribute to markers or treatments for gulf war illness (gwi).
• ·        impact and innovation are important review criteria.
• ·        preliminary data not required.
• ·        clinical trials not allowed.
• ·       biorepository contribution option: applications including a commitment to work with the gwirp-supported biorepository resource network and that meet the criteria outlined in the program announcement/funding opportunity will qualify for a higher level of funding.  application to this option is not a requirement for idea award submission.
• ·       maximum funding of $150,000 for direct costs (plus indirect costs)
• ·       maximum funding of $170,000 for direct costs with the biorepository contribution option (plus indirect costs)
• ·       maximum period of performance is 2 years
• ·       preapplication is required; application submission is by invitation only.

clinical evaluation award – preapplication due july 12, 2019

independent investigators at all academic levels

• ·       supports translation of validated gwi research, including qualified and replicated preclinical findings, to a gulf war veteran population.
• ·       statistically powered biomarker trials with the potential to validate use of biomarkers as clinical endpoints – or – proof-of-concept intervention trials (e.g., pilot, first in human, phase i-iia) are encouraged under this funding opportunity.
• ·       preliminary data required.
• ·       funding for this award mechanism must support research in a gulf war veteran population.  proof of availability and access to necessary cohort(s) and/or critical reagents must be provided.
• ·       biorepository contribution option: applications including a commitment to work with the gwirp-supported biorepository resource network and that meet the criteria outlined in the program announcement/funding opportunity will qualify for a higher level of funding. applications to this option is not a requirement for clinical evaluation award submission.
• ·       clinical consortium collaboration option: applications including a commitment to work with the gwirp-supported gulf war illness clinical trials and interventions consortium (gwictic) and that meet the criteria outlined in the program announcement/funding opportunity will qualify for a higher level of funding.  clinical consortium collaboration options applications are not eligible to also submit under the biorepository contribution option.  application to this option not a requirement for clinical evaluation award submission.
  • ·      maximum funding of $1,000,000 for direct costs (plus indirect costs)
  • ·       maximum funding of $1,020,000 for direct costs with the biorepository contribution option (plus indirect costs).
  • ·       maximum funding of $1,200,000 for direct costs with the clinical consortium collaboration option (plus indirect costs).
  • ·       maximum period of performance is 3 years
  • ·       preapplication is required; application submission is by invitation only.

therapeutic/biomarker trial award - preapplication due july 12, 2019

independent investigators at all academic levels

• ·       supports large-scale, pivotal (phase iib or iii) trials that revolutionize the clinical management of gwi.
  • ·         objective biomarkers to measure the biological effect of an investigational therapeutic or predictive/cohort-selective biomarkers that indicate whether a specific therapy will be effective in an individual with gulf war veteran or gulf war veteran subgroup must be included in the trial design.
  • ·       investigators must have experience in leading large-scale projects and demonstrated ability to implement a clinical project successfully.
  • ·       funding must be used to support a clinical trial.
  • ·       biorepository contribution option: applications including a commitment to work with the gwirp-supported biorepository resource network and that meet the criteria outlined in the program announcement/funding opportunity will qualify for a higher level of funding. application to this option is not a requirement for therapeutic/biomarker trial award submission.
  • ·        clinical consortium collaboration option: applications including a commitment to work with the gwirp-supported gulf war illness clinical trials and interventions consortium (gwictic) and that meet the criteria outlined in the program announcement/funding opportunity will qualify for a higher level of funding.  clinical consortium collaboration option applications are not eligible to also submit under the biorepository contribution option.  application to this option is not a requirement for therapeutic/biomarker trial award submission.
  • ·       funding must be used to support a clinical trial.
    • ·      maximum funding of $5,000,000 for direct costs (plus indirect costs)
    • ·      maximum funding of $5,020.000 for direct costs with the biorepository contribution option (plus indirect costs)
    • ·      maximum funding of $5,500,000 for direct costs with the clinical consortium collaboration option (plus indirect costs)
  • ·       maximum period of performance is 4 years
  • ·       preapplication is required; application submission is by invitation only.

patient-provider and health communications award - preapplication due july 12, 2019

independent investigators at or above the level of assistant professor

• ·       supports projects aimed at tools and processes to raise awareness of gwi research and clinical findings within communities, including veterans with gwi and/or their caregivers or advocates, healthcare providers who serve veterans with gwi, or public health professional relevant to veterans with gwi.
• ·       maintenance and sustainment of the dissemination effort past the award period for continued awareness of gwi research and clinical findings is an important review criterion.
• ·       must include a description of evaluation metrics and tracking to assist in measuring the success of the communication tool or process.
• ·       must include at least one gulf war veteran with gwi, who will be integral throughout the planning and implementation of the research project.
• ·       near-term impact is expected.
• ·       clinical trials are not allowed.
  • ·      maximum funding of $700,000 for direct costs (plus indirect costs)
  • ·      maximum period of performance is 3 years
  • ·       preapplication is required; application submission is by invitation only.

new investigator award - preapplication due july 12, 2019

pis may apply under one of the following three eligibility categories:

transitioning postdoctoral fellow: senior postdoctoral fellows who have completed at least 3 years of postdoctoral training

early-career investigator: independent investigators within 5 years since their last training position

new gwi researcher: established independent investigators who have received less than $300,000 in federally funded, non-mentored gwi research

• ·      encourages applications from early-stage and established investigators new to the field of gwi research.
• ·      previous experience in gwi research is not required; however, collaborations with experienced gwi researchers is strongly encouraged.
• ·      preliminary data are not required.
• ·       clinical trials are not allowed.
  • ·      biorepository contribution option: applications including a commitment to work with the gwirp-supported biorepository resource network and that meet the criteria outlined in the program announcement/funding opportunity will qualify for a higher level of funding, application to this option is not a requirement for new investigator award submission.
  • ·      maximum funding of $500,000 for direct costs (plus indirect costs)
  • ·      maximum funding of $520,000 for direct costs with the biorepository contribution option (plus indirect costs)
  • ·      the maximum period of performance is 3 years
  • ·       preapplication is required; application submission is by invitation only.

research advancement award - preapplication due july 12, 2019

independent investigators at all academic levels

• ·         supports preclinical research already supported by preliminary or published data in the gwi field that is ready for validation through expansion, replication, or comparative studies.
• ·         impact is an important review criterion.
• ·         preliminary data in the field of gwi and other supporting information is required.
• ·         clinical trials are not allowed.
• ·         biorepository contribution option: applications including a commitment to work with the gwirp-supported biorepository resource network and that meet the criteria outlined in the program announcement/funding opportunity will qualify for a higher level of funding.  application to this option is not a requirement for research advancement award submission.
• ·         preapplication is required; application submission is by invitation only.
• ·         maximum funding of $700,000 for direct costs (plus indirect costs).
• ·         maximum funding of $720,000 for direct costs with the biorepository contribution option (plus indirect costs).
• ·         maximum period of performance is 3 years.
• ·         preapplication is required; application submission is by invitation only.

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline. all applications must conform to the final program announcements and general application instructions available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrmc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage athttps://ebrap.org.  for more information about the gwirp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp help desk
301-682-5507 
help@ebrap.org

the fy19 defense appropriation provides $15 million (m) to the department of defense peer reviewed alzheimer’s research program (prarp) to support research which addresses the long-term consequences of traumatic brain injury (tbi) as they pertain to alzheimer’s disease (ad) and related dementias (adrd).  as directed by the office of the assistant secretary of defense for health affairs, the defense health agency, j9 research and development directorate manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation. the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp) at the u.s. army medical research and materiel command (usamrmc).

fy19 prarp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov website.

fy19 prarp overarching challenges and focus areas:

all applications for fy19 prarp program announcements must address at least one of the following fy19 overarching challenges.  the fy19 overarching challenges will be award mechanism-specific. 

fy19 prarp overarching challenges are listed below.

in addition to addressing one or more of the specified fy19 overarching challenges, applications should also address at least one of the following fy19 focus areas in support of the fy19 overarching challenges.  an application that proposes research outside of the fy19 focus areas is acceptable, as long as the applicant provides a strong rationale.  the focus areas will be award mechanism-specific.

the prarp fy19 focus areas are listed below.

the following is a summary of the fy19 prarp program announcements.  three award mechanisms will be offered for fy19. 

https://cdmrp.army.mil/funding/prarp

convergence science research award – letter of intent due june 26, 2019

level i:  the principal investigator (pi) must be an independent, early-career investigator within 3 years of his/her first independent faculty position (or equivalent).  

level ii: the pi must be an independent investigator at or above the level of assistant professor (or equivalent).

intent:  support innovative or novel efforts to generate research resources, tools, or research efforts for researchers and/or practitioners in health sciences.

applications must address one or more of the following fy19 prarp overarching challenges:

• ·        paucity of research resources
• ·        paucity of clinical studies
• ·        diagnostics and prognostics
  • ·         epidemiology

applications should address at least one of the following fy19 prarp focus areas:

• ·        mechanisms of pathogenesis
• ·        biomarkers
• ·        epidemiology
• ·        novel target identification
  • ·         bioinformatics

research considering pharmacologic interventions is specifically discouraged under this mechanism.

preliminary data, while not required, are encouraged.

level i:

• ·       maximum funding of $225,000 for direct costs (plus indirect costs).
• ·       maximum period of performance is 3 years.
• ·       indirect costs may be proposed in accordance with the institution's rate agreement.

level ii:

• ·       maximum funding of $500,000 for direct costs (plus indirect costs).
• ·       maximum period of performance is 3 years.
• ·       indirect costs may be proposed in accordance with the institution's rate agreement.

innovation in care and support award – letter of intent due june 26, 2019

level 1: the pi must be an independent, early-career investigator within 3 years of his/her first independent faculty position (or equivalent).

level ii: the pi must be an independent investigator at or above the level of assistant professor (or equivalent)

intent: to support innovative research that improves the quality of life and care for individuals living with the common symptoms of tbi and/or ad/adrd and/or their families and care providers.

applications must address one or more of the following fy19 prarp overarching challenges:

• ·        paucity of clinical studies
• ·        diagnostics and prognostics
  • ·         epidemiology
  • ·         quality of life
  • ·         family and care support

applications should address at least one of the following fy19 prarp focus areas:

• ·        biomarkers
• ·        quality of life
• ·        family and caregiver support
• ·        epidemiology
• ·        nonpharmacological interventions and devices
  • ·         bioinformatics
  • ·       research considering pharmacologic interventions is specifically discouraged under this mechanism.
  • ·       preliminary data, while not required, are encouraged.

level i:

• ·       maximum funding of $225,000 for direct costs (plus indirect costs).
• ·       maximum period of performance is 3 years.
• ·       indirect costs may be proposed in accordance with the institution's rate agreement.

level ii:

• ·       maximum funding of $500,000 for direct costs (plus indirect costs).
• ·       maximum period of performance is 3 years.
• ·       indirect costs may be proposed in accordance with the institution's rate agreement

research partnership award – letter of intent due june 26, 2019

the pi must be an independent investigator at or above the level of assistant professor (or equivalent).

intent: to create an avenue for collaborative research partnerships between/among investigators to address a research problem or question in a manner that would be unachievable through separate efforts.

applications must include clearly stated plans for interactions between the partners.

applications must address one or more of the following fy19 prarp overarching challenges:

• ·        paucity of research resources
• ·        paucity of clinical studies
• ·        diagnostics and prognostics
  • ·         epidemiology
  • ·         quality of life
  • ·         family and care support

applications should address at least one of the following fy19 prarp focus areas:

• ·        mechanisms of pathogenesis
• ·        biomarkers
• ·        quality of life
• ·        family and caregiver support
• ·        epidemiology
• ·        novel target identification
• ·        nonpharmacological interventions and devices
  • ·         bioinformatics
  • ·       research considering pharmacologic interventions is specifically discouraged under this mechanism.
  • ·       preliminary data are required.
  • ·       funding limit is $1.3m in total costs. 
  • ·       maximum period of performance is 3 years.
  • ·       indirect costs may be proposed in accordance with the institution’s rate agreement.

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline. all applications must conform to the final program announcements and general application instructions available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrmc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage athttps://ebrap.org.  for more information about the prarp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp help desk 
301-682-5507 
help@ebrap.org

what is this prize?

the killam prizes are awarded to active canadian scholars who have made a substantial and significant contribution to their respective fields in the humanities, social sciences, natural sciences, health sciences or engineering.

prize amount

up to five prizes of $100,000 each (one prize per discipline)

the national housing strategy demonstrations initiative (demonstrations) provides a platform to:

• create and disseminate real-world data and information on affordable housing
• improve the performance, viability and effectiveness of affordable housing solutions
• foster a culture of innovation in the affordable housing sector that will better meet the housing needs of canadians

the demonstrations initiative offers solutions aiming to:

• strengthen, better equip and innovate the affordable housing sector
• increase stakeholder’s awareness, knowledge and acceptance of promising innovations
• create and disseminate real-world data for evidence-based decision-making

demonstrations showcase innovative: practices, technologies, programs, policies and strategies.
demonstration formats include on-site tours, virtual tours, best-practices guides, case studies, factsheets, website content, user experience videos, surveys and innovation profiles.